Jim Simons Cardiff Oncology, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 86,100 shares of CRDF stock, worth $194,585. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,100

Previous 116,400 26.03%

Holding current value

$194,585

Previous $172,000 167.44%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.46 - $5.91 $44,238 - $179,073	-30,300 Reduced 26.03%	86,100 $460,000
Q4 2023 Feb 13, 2024	SELL	$0.96 - $1.55 $36,096 - $58,280	-37,600 Reduced 24.42%	116,400 $172,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $2.18 $217,060 - $342,892	-157,290 Reduced 50.53%	154,000 $214,000
Q2 2023 Aug 11, 2023	SELL	$1.37 - $1.95 $27,424 - $39,035	-20,018 Reduced 6.04%	311,290 $458,000
Q1 2023 May 12, 2023	SELL	$1.45 - $2.09 $231,538 - $333,735	-159,682 Reduced 32.52%	331,308 $547,000

Q4 2022 Feb 13, 2023	BUY	$1.22 - $1.59 $84,182 - $109,713	69,002 Added 16.35%	490,990 $687,000
Q3 2022 Nov 14, 2022	SELL	$1.57 - $3.21 $479,835 - $981,065	-305,628 Reduced 42.0%	421,988 $650,000
Q2 2022 Aug 12, 2022	BUY	$1.17 - $2.61 $276,304 - $616,372	236,158 Added 48.05%	727,616 $1.6 Million
Q1 2022 May 13, 2022	BUY	$2.11 - $7.25 $1.04 Million - $3.56 Million	491,458 New	491,458 $1.22 Million
Q3 2020 Nov 13, 2020	SELL	$4.25 - $14.19 $1.14 Million - $3.81 Million	-268,800 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$0.78 - $5.1 $209,664 - $1.37 Million	268,800 New	268,800 $1.35 Million

Others Institutions Holding CRDF

# of Institutions

Shares Held

8.48M

Call Options Held

798K

Put Options Held

39.2K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $97.9M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account